Why the study?
What is the absolute bioavailability of edoxaban and the effect of the P-glycoprotein inhibitor quinidine on its pharmacokinetics in healthy subjects?
Population
36 healthy volunteers
Design
RCT, Randomized sequence
Key result
Edoxaban oral absolute bioavailability was 61.8% in healthy volunteers, and concomitant quinidine increased total edoxaban exposure by ~35%.
Authors
Loading...
Increased edoxaban exposure with quinidine warrants P-gp interaction caution; extends bioavailability data for NOAC dosing in atrial fibrillation.
RCT (n=36)
randomized sequence
What is the absolute bioavailability of edoxaban and the effect of the P-glycoprotein inhibitor quinidine on its pharmacokinetics in healthy subjects?
Edoxaban has an absolute oral bioavailability of 61.8% in healthy subjects, and its exposure is moderately increased by the P-glycoprotein inhibitor quinidine.
Matsushima et al. (2013) conducted an RCT in Healthy volunteers (n=36). Edoxaban vs. Different administration routes and concomitant quinidine was evaluated on Absolute bioavailability of edoxaban. Edoxaban oral absolute bioavailability was 61.8% in healthy volunteers, and concomitant quinidine increased total edoxaban exposure by ~35%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: